Is AbbVie Stock a Buy?

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising its dividend by an average of 14% annually. That sustained yield and growth have made shareholders very happy.For most of those years, AbbVie enjoyed lucrative success with Humira. However, the company's revenue has dipped since Humira lost patent exclusivity in 2023, and the stock price has only increased by 6% over the past two years (not counting dividends).Are AbbVie's best years behind it? Or is the company retooling for another stretch of prosperity? Let's decide whether AbbVie is a buy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool